Clinical Trial Update: Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes [Phase 2]

View source ↗

Summary

Phase II pilot study evaluating cisplatin with metronomic cyclophosphamide in metastatic, stage IV triple-negative breast cancer resistant to anthracyclines and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Cyclophosphamide (metronomic) (cyclophosphamide)

Snippet

Sponsor: Centre Jean Perrin | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED